Melanotan I vs Melanotan II for Research
Melanotan I (MT-I/afamelanotide-related material) and Melanotan II (MT-II) are not two strengths of the same peptide. They are structurally distinct melanocortin analogues with different experimental histories. The correct comparison starts with molecular form and receptor context, not with tanning or consumer-use claims.
MT-I is a linear alpha-MSH analogue
[Nle4,D-Phe7]-alpha-MSH has been used as a modified alpha-MSH analogue in melanocortin research. Early comparative experiments found prolonged melanotropic activity relative to native alpha-MSH in chromatophore models. PubMed.
Radioligand work in human melanoma-cell systems showed high-affinity competition at alpha-MSH binding sites. PubMed. These experiments describe a defined analogue and assay; they do not establish the exact identity of every commercial MT-I product.
MT-II is a cyclic melanocortin analogue
Melanotan II is described in the literature as a cyclic heptapeptide alpha-MSH analogue used as a relatively non-selective melanocortin-receptor agonist. PubMed. Receptor studies show activity across several melanocortin-receptor subtypes, with potency depending on the receptor and assay. PubMed.
Side-by-side research distinction
| Feature | MT-I-related analogue | MT-II |
|---|---|---|
| General scaffold | Linear alpha-MSH-derived analogue | Cyclic melanocortin analogue |
| Research history | Melanotropic activity, receptor binding and cell-response heterogeneity | Multi-receptor melanocortin pharmacology in several experimental systems |
| Receptor interpretation | Should be stated for the exact assay rather than called universally MC1R-selective | Relatively broad melanocortin-receptor agonism; potency varies by subtype/assay |
| Can sequence/mass be transferred? | No. Exact product identity and terminal form must be documented separately. | |
Model variability matters
MT-I-related research in human melanoma cell lines found increased tyrosinase activity in only a subset of the tested lines. PubMed. MT-II studies span different endpoints, including neuroendocrine/feeding models and peripheral-nerve injury models. Feeding model; nerve model.
Those results should not be compressed into a claim that one analogue is simply “stronger”. They measure different biology under different conditions.
Product identity and documentation
The exact sequence, cyclisation/terminal modifications, salt/counter-ion, mass and lot-specific analytical results for a supplied product belong to the applicable batch record. Shared melanocortin terminology is not enough to establish equivalence.
Use Batch Documentation and the CoA-reading guide for product/lot evidence.
Catalogue routes
Core Research lists Melanotan I (MT-1) 10mg and Melanotan II (MT-2) 10mg, plus refill/pen presentations. The format does not change the need to identify the exact compound.
Research-use boundary
This comparison does not provide tanning, pigmentation, dosing, administration or human-use guidance. Core Research melanocortin materials are supplied for laboratory research only, not for human or veterinary use.